Results 1 to 10 of about 30,636 (152)

Cortical Lewy Body Dementia [PDF]

Behavioural Neurology, 1990
In cortical Lewy body dementia the distribution of Lewy bodies in the nervous system follows that of Parkinson's disease, except for their greater profusion in the cerebral cortex. The cortical tangles and plaques of Alzheimer pathology are often present,
W. R. G. Gibb
doaj   +3 more sources

Evidence for divergent cortical organisation in Parkinson’s disease and Lewy Body Dementia [PDF]

Nature Communications
Dementia is a defining feature of Lewy body disease: its timing and onset distinguish different clinical diagnoses, and its effect on quality of life is profound.
Angeliki Zarkali, George Thomas, Naomi Hannaway, Ivelina Dobreva, Melissa Grant Peters, Martina F. Callaghan, Mina Ryten, Rimona S. Weil   +7 more
doaj   +2 more sources

Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies [PDF]

Molecular Neurodegeneration
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
Hiroaki Sekiya, Tomoyasu Matsubara, Michael A. DeTure, Dennis W. Dickson   +3 more
doaj   +2 more sources

Research models to study lewy body dementia [PDF]

Molecular Neurodegeneration
Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer’s disease (AD) remains complex due to symptom overlap, yet ...
Suelen Lucio Boschen, Aarushi A. Mukerjee, Ayman H. Faroqi, Ben E. Rabichow, John Fryer   +4 more
doaj   +2 more sources

Dementia with Lewy bodies [PDF]

Psychiatry, 1999
Objective: The aim of this paper is to summarise recent clinical and research findings with regard to dementia with Lewy bodies (DLB). Method: A literature review (Medline) was carried out, as well as a review of reports of recent DLB symposia of international meetings and of other relevant papers and data known to the authors.
I, McKeith, J, O'Brien
openaire   +14 more sources

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology

Metabolites, 2021
Ubiquitin Specific Protease-13 (USP13) promotes protein de-ubiquitination and is poorly understood in neurodegeneration. USP13 is upregulated in Alzheimer’s disease (AD) and Parkinson’s disease (PD), and USP13 knockdown via shRNA reduces neurotoxic ...
Xiaoguang Liu, Kaluvu Balaraman, Ciarán C. Lynch, Michaeline Hebron, Christian Wolf, Charbel Moussa   +5 more
doaj   +1 more source

Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium

Frontiers in Neurology, 2022
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and ...
Gregory D. Scott, Gregory D. Scott, Moriah R. Arnold, Thomas G. Beach, Christopher H. Gibbons, Anumantha G. Kanthasamy, Russell M. Lebovitz, Afina W. Lemstra, Leslie M. Shaw, Charlotte E. Teunissen, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Angela S. Taylor, Todd C. Graham, Bradley F. Boeve, Stephen N. Gomperts, Neill R. Graff-Radford, Charbel Moussa, Kathleen L. Poston, Liana S. Rosenthal, Marwan N. Sabbagh, Ryan R. Walsh, Miriam T. Weber, Melissa J. Armstrong, Jee A. Bang, Andrea C. Bozoki, Kimiko Domoto-Reilly, John E. Duda, John E. Duda, Jori E. Fleisher, Douglas R. Galasko, James E. Galvin, Jennifer G. Goldman, Samantha K. Holden, Lawrence S. Honig, Daniel E. Huddleston, James B. Leverenz, Irene Litvan, Carol A. Manning, Karen S. Marder, Alexander Y. Pantelyat, Victoria S. Pelak, Douglas W. Scharre, Sharon J. Sha, Holly A. Shill, Zoltan Mari, Joseph F. Quinn, Joseph F. Quinn, David J. Irwin, David J. Irwin, David J. Irwin, David J. Irwin   +54 more
doaj   +1 more source

Lewy body dementias [PDF]

The Lancet, 2015
The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years.
Walker, Zuzana, Possin, Katherine L, Boeve, Bradley F, Aarsland, Dag   +3 more
openaire   +5 more sources

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for ...
Fernando L. Pagan, Yasar Torres‐Yaghi, Michaeline L. Hebron, Barbara Wilmarth, R. Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa   +8 more
doaj   +1 more source

Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting

Alzheimer’s Research & Therapy, 2021
In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments.
Jennifer G. Goldman, Bradley F. Boeve, Melissa J. Armstrong, Doug R. Galasko, James E. Galvin, David J. Irwin, James B. Leverenz, Karen Marder, Victor Abler, Kevin Biglan, Michael C. Irizarry, Bill Keller, Robert Lai, Leanne Munsie, Michael Belleville, Ondrea Chaney, Ian Richard, Angela Taylor, Todd Graham   +18 more
doaj   +1 more source